Dr. Odenike is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5841 S. MARYLAND
M/C 2115
Chicago, IL 60637Phone+1 773-702-3354Fax+1 773-702-3002- Is this information wrong?
Education & Training
- University of ChicagoFellowship, Hematology and Medical Oncology, 1994 - 1997
- University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 1990 - 1994
- University of IbadanClass of 1988
- University of IfeNo degree, Preliminary Science Studies, 1982 - 1983
Certifications & Licensure
- IL State Medical License 1990 - 2026
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Listed in Castle Connolly’s Top Doctors 2014
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Join now to see all
Clinical Trials
- Imatinib Mesylate in Treating Patients With Myelofibrosis Start of enrollment: 2002 Apr 01
- Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2003 May 01
- 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies Start of enrollment: 2004 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia.Farhad Ravandi, Asad Bashey, James M Foran, Wendy Stock, Raya Mawad, Nicholas J Short, Musa Yilmaz, Hagop M Kantarjian, Olatoyosi Odenike, Anand A Patel, Raman Garcha,...> ;Blood Advances. 2023 Aug 30
- Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Cons...Maximilian Stahl, Jan Philipp Bewersdorf, Zhuoer Xie, Matteo Giovanni Della Porta, Rami Komrokji, Mina L Xu, Omar Abdel-Wahab, Justin Taylor, David P Steensma, Daniel ...> ;Blood Reviews. 2023 Aug 19
- Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia.Caner Saygin, Giorgia Giordano, Kathryn Shimamoto, Bart Eisfelder, Anika Thomas-Toth, Girish Venkataraman, Vijayalakshmi Ananthanarayanan, Tiffaney L Vincent, Adam DuV...> ;Clinical Cancer Research. 2023 Aug 15
- Join now to see all
Journal Articles
- How I Treat Blast Phase of Philadelphia-Negative Myeloproliferative NeoplasmsOlatoyosi Odenike, MD, Blood
- Clinical Cancer Advances 2015: annual report on progress against cancer from the American Society of clinical oncologyMasters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O’Day SJ, Odenike O, Ryan CJ, Schilsky RL, Sc..., J Clin Oncol, 1/1/2015
- Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: an update on risk stratification, molecular genetics, and therapeutic approaches including ...Odenike O, Onida F, Padron E, Am Soc Clin Oncol Educ Book, 1/1/2015
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH InhibitorsOlatoyosi Odenike, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodyspl...Olatoyosi Odenike, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDSOlatoyosi Odenike, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Results from the first-in-human study of mivebresib (ABBV-075), a pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory acute ...2019 ASCO Annual Meeting - 6/1/2019
- A Multi-Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Rela...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Imetelstat, what is the best setting?Dallas, TX - 1/1/2016
- Join now to see all
Other
- ”Ibrutinib will change the CLL landscape” Expert opinion on CLL Resonate Ibrutinib studyOncology times
1/1/2014 - It takes more than a JAK-hammer to crack the caseASH News Daily
1/1/2013 - Nature Reviews Drug Discovery 10: 717-18, Companies hope for kinase inhibitor JAKpotNews and Analysis
1/1/2011 - Join now to see all
Press Mentions
- ASCO: Bristol Myers' $4B Plan for Reblozyl Takes Shape in Blood Cancer Anemia—with One CaveatMay 25th, 2023
- Ponatinib May Be More Effective Than Imatinib for Newly Diagnosed Patients with Ph-Positive ALLFebruary 15th, 2023
- Pharmacyclics, J&J Drug Shown to Improve Leukemia SurvivalMay 31st, 2014
- Join now to see all
Hospital Affiliations
- University of Chicago Medical CenterChicago, Illinois
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: